{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:12:28Z","timestamp":1793592748340,"version":"4.5.0"},"reference-count":47,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Infants are often assumed to be immune to measles through maternal antibodies transferred during pregnancy and, in many countries, receive their first measles-containing vaccine at 12 to 15 months. Immunity may wane before this time in measles-eliminated settings, placing infants at risk for measles and complications. We investigated humoral immunity to measles in infants &amp;lt;12 months of age in Ontario, Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We selected sera collected at a tertiary pediatric hospital from infants &amp;lt;12 months who were born at \u226537 weeks\u2019 gestational age. We excluded infants with conditions that affect antibody levels. We selected \u226425 sera from 8 predetermined age bands and tested them for measles-neutralizing antibody using the plaque-reduction neutralization test. We calculated the proportion immune at each age band, and predictors of infant susceptibility were assessed by using multivariable logistic regression and Poisson regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of 196 infant sera, 56% (110 of 196) were from boys, and 35% (69 of 196) were from infants with underlying medical conditions. In the first month, 20% (5 of 25) of infants had antibodies below the protective threshold, which increased to 92% (22 of 24) by 3 months. By 6 months, all infants had titers below the protective threshold. In a multivariable analysis, infant age was the strongest predictor of susceptibility (odds ratio = 2.13 for each additional month increase; 95% confidence interval: 1.52\u20132.97).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Most infants were susceptible to measles by 3 months of age in this elimination setting. Our findings inform important policy discussions relating to the timing of the first dose of measles-containing vaccine and infant postexposure prophylaxis recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2019-0630","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T13:25:15Z","timestamp":1574342715000},"source":"Crossref","is-referenced-by-count":45,"title":["Measles Antibody Levels in Young Infants"],"prefix":"10.1542","volume":"144","author":[{"given":"Michelle","family":"Science","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Paediatrics, and"},{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Departments of Paediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Savage","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Severini","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada;"},{"name":"Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McLachlan","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Arnold","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Paediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Richardson","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Crowcroft","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada;"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;"},{"name":"ICES, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Deeks","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Halperin","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS), Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Brown","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;"},{"name":"ICES, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hatchette","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS), Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gubbay","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Paediatrics, and"},{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Departments of Paediatrics and"},{"name":"Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mazzulli","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada;"},{"name":"Mount Sinai Hospital, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Bolotin","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada;"},{"name":"Laboratory Medicine and Pathobiology, University of Toronto, Toronto Canada;"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"key":"2021121022514404000_B1","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics Committee on Infectious Diseases","year":"2015","edition":"30th ed"},{"key":"2021121022514404000_B2","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario) . Reportable disease trends in Ontario, 2014. 2016. Available at: https:\/\/www.publichealthontario.ca\/en\/eRepository\/Reportable_disease_trends_in_Ontario_2014.pdf. Accessed October 17, 2019"},{"key":"2021121022514404000_B3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/377693","article-title":"Measles elimination in the United States","volume":"189","author":"Orenstein","year":"2004","journal-title":"J Infect Dis"},{"issue":"12","key":"2021121022514404000_B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14745\/ccdr.v40i12a01","article-title":"Measles surveillance in Canada: trends for 2013","volume":"40","author":"Shane","year":"2014","journal-title":"Can Commun Dis Rep"},{"key":"2021121022514404000_B5","unstructured":"Centers for Disease Control and Prevention. Complications of measles. 2018. Available at: www.cdc.gov\/measles\/about\/complications.html. Accessed April 22, 2019"},{"issue":"18","key":"2021121022514404000_B6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMra012493","article-title":"Maternal antibodies, childhood infections, and autoimmune diseases","volume":"345","author":"Zinkernagel","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121022514404000_B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S0950268899002046","article-title":"Transplacental transfer of measles and total IgG","volume":"122","author":"Gon\u00e7alves","year":"1999","journal-title":"Epidemiol Infect"},{"issue":"6\u20137","key":"2021121022514404000_B8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0264-410X(96)00283-6","article-title":"Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles","volume":"15","author":"De Serres","year":"1997","journal-title":"Vaccine"},{"issue":"17","key":"2021121022514404000_B9","first-page":"205","article-title":"Measles vaccines: WHO position paper \u2013 April 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"2021121022514404000_B10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1017\/S095026880005442X","article-title":"Maternally derived measles immunity in children of naturally infected and vaccinated mothers","volume":"101","author":"Jenks","year":"1988","journal-title":"Epidemiol Infect"},{"issue":"7","key":"2021121022514404000_B11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00006454-199207000-00004","article-title":"Reduced measles immunity in infants in a well-vaccinated population","volume":"11","author":"Pabst","year":"1992","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2021121022514404000_B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00006454-199901000-00013","article-title":"Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines","volume":"18","author":"Whittle","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"31","key":"2021121022514404000_B13","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1016\/S0264-410X(03)00449-3","article-title":"Modelling measles re-emergence as a result of waning of immunity in vaccinated populations","volume":"21","author":"Mossong","year":"2003","journal-title":"Vaccine"},{"key":"2021121022514404000_B14","doi-asserted-by":"crossref","first-page":"c1626","DOI":"10.1136\/bmj.c1626","article-title":"Early waning of maternal measles antibodies in era of measles elimination: longitudinal study","volume":"340","author":"Leuridan","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"2021121022514404000_B15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jit143","article-title":"Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage","volume":"208","author":"Waaijenborg","year":"2013","journal-title":"J Infect Dis"},{"key":"2021121022514404000_B16","unstructured":"Public Health Agency of Canada . Measles Vaccine: Canadian Immunization Guide. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-12-measles-vaccine.html#p4c11a5. Accessed October 17, 2019"},{"issue":"10","key":"2021121022514404000_B17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2018.01.002","article-title":"Waning of measles maternal antibody in infants in measles elimination settings - a systematic literature review","volume":"36","author":"Guerra","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"2021121022514404000_B18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0027-9684(15)31545-5","article-title":"Immunity to measles in pregnant mothers and in cord blood of their infants: impact of HIV status and mother\u2019s place of birth","volume":"100","author":"Choudhury","year":"2008","journal-title":"J Natl Med Assoc"},{"issue":"27","key":"2021121022514404000_B19","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/j.vaccine.2015.04.104","article-title":"Maternally acquired IgG immunity in neonates born to renal transplanted women","volume":"33","author":"Viana","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"2021121022514404000_B20","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3346\/jkms.2016.31.12.1957","article-title":"Seroprevalences of specific IgG antibodies to measles, mumps, and rubella in Korean infants","volume":"31","author":"Cho","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"9","key":"2021121022514404000_B21","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.4049\/jimmunol.162.9.5569","article-title":"IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants","volume":"162","author":"Gans","year":"1999","journal-title":"J Immunol"},{"issue":"7","key":"2021121022514404000_B22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1086\/323346","article-title":"Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months","volume":"184","author":"Gans","year":"2001","journal-title":"J Infect Dis"},{"issue":"1","key":"2021121022514404000_B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/421032","article-title":"Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States","volume":"190","author":"Gans","year":"2004","journal-title":"J Infect Dis"},{"key":"2021121022514404000_B24","volume-title":"Immunization Coverage Report for School Pupils in Ontario: 2013\u201314, 2014\u201315 and 2015\u201316 School Years","author":"Ontario Agency for Public Health Protection and Promotion (Public Health Ontario)","year":"2017"},{"key":"2021121022514404000_B25","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1086\/378499","article-title":"Measles elimination in Canada","volume":"189","author":"King","year":"2004","journal-title":"J Infect Dis"},{"issue":"2","key":"2021121022514404000_B26","doi-asserted-by":"crossref","first-page":"ofv048","DOI":"10.1093\/ofid\/ofv048","article-title":"Measles in Canada between 2002 and 2013","volume":"2","author":"De Serres","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2021121022514404000_B27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"issue":"1","key":"2021121022514404000_B28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"2021121022514404000_B29","doi-asserted-by":"crossref","first-page":"e00269","DOI":"10.1128\/CVI.00269-16","article-title":"Calibration and evaluation of quantitative antibody titers for measles virus by using the BioPlex 2200","volume":"24","author":"Hatchette","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2021121022514404000_B30","unstructured":"Gould\u2008W. Use poisson rather than regress; tell a friend. Available at: https:\/\/blog.stata.com\/2011\/08\/22\/use-poisson-rather-than-regress-tell-a-friend\/. Accessed October 17, 2019."},{"key":"2021121022514404000_B31","volume-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","year":"2010","edition":"2nd ed"},{"issue":"10","key":"2021121022514404000_B32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/aje\/kww093","article-title":"Statistical methods for unusual count data: examples from studies of microchimerism","volume":"184","author":"Guthrie","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2021121022514404000_B33","first-page":"ACS","article-title":"Guidelines for the prevention and control of measles outbreaks in Canada","volume":"39","author":"Public Health Agency of Canada Measles and Rubella Elimination Working Group","year":"2013","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"2021121022514404000_B34","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/infdis\/jix453","article-title":"Measles antibodies in mother-infant dyads in Tianjin, China","volume":"216","author":"Boulton","year":"2017","journal-title":"J Infect Dis"},{"issue":"24","key":"2021121022514404000_B35","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.vaccine.2016.04.007","article-title":"Measles antibodies in cord blood in Portugal: possible consequences for the recommended age of vaccination","volume":"34","author":"Gon\u00e7alves","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"2021121022514404000_B36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcv.2006.12.017","article-title":"Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests","volume":"38","author":"Tischer","year":"2007","journal-title":"J Clin Virol"},{"issue":"50","key":"2021121022514404000_B37","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2008.08.074","article-title":"Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination","volume":"26","author":"Cohen","year":"2008","journal-title":"Vaccine"},{"key":"2021121022514404000_B38","volume-title":"Immunological Basis for Immunization: Measles - Update 2009","author":"World Health Organization","year":"2009"},{"issue":"5","key":"2021121022514404000_B39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(77)81021-4","article-title":"Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure","volume":"91","author":"Albrecht","year":"1977","journal-title":"J Pediatr"},{"key":"2021121022514404000_B40","volume-title":"Measles Vaccination Below 9 Months of Age: Systematic Literature Review and Meta-Analyses of Effects and Safety","author":"Lochlainn","year":"2015"},{"issue":"50","key":"2021121022514404000_B41","first-page":"681","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2015 \u2013 conclusions and recommendations","volume":"90","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"issue":"RR-04","key":"2021121022514404000_B42","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2015;64(9):259]","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"2021121022514404000_B43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/07853890.2017.1417632","article-title":"Challenges in adult vaccination","volume":"50","author":"de Gomensoro","year":"2018","journal-title":"Ann Med"},{"key":"2021121022514404000_B44","unstructured":"Centers for Disease Control and Prevention. Reproductive health. Available at: https:\/\/www.cdc.gov\/reproductivehealth. Accessed November 18, 2018"},{"issue":"5","key":"2021121022514404000_B45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.12968\/hmed.2019.80.5.298","article-title":"Vaccine hesitancy: a major global health risk","volume":"80","author":"Walsh","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"2021121022514404000_B46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12879-015-1039-0","article-title":"Global travel patterns and risk of measles in Ontario and Quebec, Canada: 2007-2011","volume":"15","author":"Wilson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"7","key":"2021121022514404000_B47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14745\/ccdr.v42i07a01","article-title":"Measles surveillance in Canada: 2015","volume":"42","author":"Sherrard","year":"2016","journal-title":"Can Commun Dis Rep"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-0630\/1078363\/peds_20190630.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-0630\/1078363\/peds_20190630.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T06:12:15Z","timestamp":1695449535000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/144\/6\/e20190630\/37957\/Measles-Antibody-Levels-in-Young-Infants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,12,1]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-0630","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]},"article-number":"e20190630"}}